Download MendeleyEnozertinib is a Selective, Brain-penetrant EGFR inhibitor for Treating Non-small Cell Lung Cancers with EGFR Exon 20 and Atypical Mutations.
Junttila, M.R., Repellin, C.E., Salaniwal, S., Warne, R., Lee, Y., Kim, H., Seo, K.A., Lee, Y., Jung, H.R., Baik, J., Chang, J.H., Andreatta, G., Long, J.E., Sun, J.D., Ni, S.W., Soroceanu, L., Sambucetti, L.C., Das, A., Chan, B., Narayanan, P., Pereira, A.S., Chow Maneval, E., Multani, P.S., Patel, R., Panuwat, M., Blank, B.R., Ndubaku, C., Romero, F.A., Daemen, A., Spira, A.I., Friedman, L.S.(2025) Cancer Res
- PubMed: 41196054
- DOI: https://doi.org/10.1158/0008-5472.CAN-25-3502
- Primary Citation of Related Structures:
9U8C - PubMed Abstract:
EGFR mutations are common oncogenic drivers in non-small cell lung cancer (NSCLC), and around one-third of patients develop brain metastases over the course of their disease. Patients with non-classical EGFR mutations, such as insertions in exon 20, are a high unmet need with a worse prognosis compared to patients with classical EGFR mutations. Here, we describe the discovery and development of enozertinib (formerly ORIC-114), a highly brain-penetrant, orally bioavailable, irreversible inhibitor that targets EGFR exon 20 mutations with unparalleled kinome selectivity. Preclinical studies revealed strong potency and tumor regressions driven by enozertinib across a broad range of atypical EGFR mutant models. In a phase I clinical trial of enozertinib in patients with advanced NSCLC bearing atypical mutations in EGFR, a patient with harboring an EGFR exon 20 insertion experienced sustained complete response of all systemic and brain metastases. Together, these findings identify enozertinib as a promising investigational inhibitor to meet the unmet need for brain-penetrant therapies for NSCLC with EGFR exon 20 insertions or other atypical mutations.
- ORIC Pharmaceuticals, Inc., South San Francisco, CA, United States.
Organizational Affiliation:
